FGF2 and Parkinson disease: Intranasal gelatin-based NLCs have been used in research for delivery of basic fibroblast growth factor (bFGF) and shown efficient brain targeting, neuroprotection, and functional recovery in PD rat models without causing nasal tissue damage [209,210].